Please ensure Javascript is enabled for purposes of website accessibility

Sorrento Therapeutics to Buy Its Coronavirus Vaccine Development Partner

By Cory Renauer – Jul 24, 2020 at 3:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sorrento intends to acquire SmartPharm to develop its pipeline of gene-encoded antibodies to treat COVID-19 and cancer.

Sorrento Therapeutics (SRNE -0.63%) made another committment toward developing new COVID-19 treatments and vaccines on Friday. The company has entered into a letter of intent to acquire privately held SmartPharm Therapeutics and its pipeline of non-viral gene therapies. The deal is expected to close next month; financial terms weren't disclosed.

Gene therapies generally rely on viral vectors to deliver genetic material, but this procedure adds a thick layer of complexity to the manufacturing process. Reactions are rare, but unexpected immune responses are another issue for viral-vector technology. SmartPharm's approach involves delivering strands of DNA and messenger RNA directly to cells with simple injections that don't involve any viral vectors.

Healthcare provider holding a coronavirus vial.

Image source: Getty Images.

In March, Sorrento and SmartPharm began collaborating on injectable gene therapies that lead to the production of antibodies originally discovered by Sorrento to fight SARS-CoV-2, the virus that causes COVID-19.

The first candidate to enter clinical trials using SmartPharm's delivery technology will most likely be based on STI-1499, which is currently miles behind the front runners in the race to develop a coronavirus vaccine. The company still hasn't submitted an investigational new drug application (IND) for STI-1499 or the version to be encoded on a DNA plasmid injection called STI-1499dpi.

An approved IND is a pre-requisite to begin clinical trials in the U.S., and the company doesn't plan to submit an application until next month for STI-1499. There's still no telling when STI-1499dpi will be ready for its first human proof-of-concept trial.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
$1.57 (-0.63%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.